Scientific and Clinical Challenges in Sepsis
Authors:
- Luis UlloaLULuis Ulloa
- Michael BrunnerMBMichael Brunner
- Laura RamosLRLaura Ramos
- Edwin A. DeitchEDEdwin A. Deitch
- 1 June 2009
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 15 (16) , 1918-1935
Abstract
Advances in intensive care and antibiotics have prevented the spread of some infections, though sepsis mortality rates remain high. With failure of over thirty clinical trials, sepsis remains a scientific and clinical challenge in modern medicine. Sepsis is defined by the clinical signs of a systemic inflammatory response to infection. “Severe sepsis” is when these symptoms are associated with multiple organ dysfunction. These definitions of sepsis may be too broad and common to heterogeneous groups of patients who do not necessarily have the same disorder. This consideration has become especially evident in the clinical trials that have failed to obtain consistent results in similar studies of patients diagnosed with severe sepsis. In these trials, patients with infections caused by different microorganisms, and affecting different organs, have been combined under the general diagnosis of severe sepsis. The situation is analogous to attempting a clinical trial based on the general definition of cancer, combining all patients with tumor independent of the type of malignancy. In this consideration, it would not be very surprising that activated protein C, the only treatment in sepsis approved by the Food and Drug Administration, is projected for use in only a small subset of patients with severe sepsis. This article reviews novel inflammatory molecular aspects and the experimental anti-inflammatory strategies for sepsis, as they may represent particular pathological processes in specific subsets of patients.Keywords
This publication has 202 references indexed in Scilit:
- The X-ray Crystal Structure of the NF-κB p50·p65 Heterodimer Bound to the Interferon β-κB SiteJournal of Biological Chemistry, 2002
- Experimental models of Gram-negative sepsisBritish Journal of Surgery, 2001
- Control of apoptosis by Rel/NF-κB transcription factorsOncogene, 1999
- A Comparative Study on the Effects of Nicotine and GTS-21, a New Nicotinic Agonist, on the Locomotor Activity and Brain Monoamine LevelThe Japanese Journal of Pharmacology, 1998
- Introducing Critical Appraisal to studies of animal models investigating novel therapies in sepsisCritical Care Medicine, 1996
- Macrophage Elimination Increases Bacterial Translocation and Gut-Origin Septicemia but Attenuates Symptoms and Mortality Rate in a Model of Systemic InflammationAnnals of Surgery, 1993
- Detection of Circulating Tumor Necrosis Factor after Endotoxin AdministrationNew England Journal of Medicine, 1988
- A Controlled Clinical Trial of High-Dose Methylprednisolone in the Treatment of Severe Sepsis and Septic ShockNew England Journal of Medicine, 1987
- Gram-negative bacteremia produces both severe systolic and diastolic cardiac dysfunction in a canine model that simulates human septic shock.Journal of Clinical Investigation, 1986
- The Effects of High-Dose Corticosteroids in Patients with Septic ShockNew England Journal of Medicine, 1984